Not investment advice. Educational platform. See Disclaimer.
NYSE: LLY
Eli Lilly and Company
Healthcare | Drug Manufacturers - General
$1,160.08as of 2026-09-03 10:20 UTC
Market Cap$1.04T
EPS (TTM)$22.95
Eli Lilly and Company (NYSE: LLY) is a $1.04T drug manufacturers - general company trading at $1,160.08 — 50.5× trailing earnings, yielding 0.52%. Figures from SEC EDGAR and market feeds; updated 2026-09-03 10:20 UTC.
52-Week Range
Low $850.51High $1,292.65
What Eli Lilly and Company does
Eli Lilly and Company, incorporated in 1901, is a pharmaceutical manufacturer that discovers, develops, and markets human pharmaceutical products globally. The company operates manufacturing and distribution facilities in the United States, Puerto Rico, Europe, and Asia, selling products in approximately 90 countries. Lilly's product portfolio spans multiple therapeutic areas, including cardiometabolic health treatments such as various insulin formulations and newer diabetes medications, as well as obesity and cardiovascular disease treatments.
Summarized from Eli Lilly and Company’s SEC filings · Read the filing ↗
Eli Lilly and Company, incorporated in 1901, is a pharmaceutical manufacturer that discovers, develops, and markets human pharmaceutical products globally.
What is LLY's valuation?
LLY trades at $1,160.08, 50.55× trailing earnings, as of 2026-09-03. It carries a 0.52% dividend yield.
When did LLY last file with the SEC?
Eli Lilly and Company's most recent SEC filing on record is a 10-Q filed 2026-08-05. All filings link to their SEC EDGAR originals above.
Where does this data come from?
SEC EDGAR filings and public market data feeds, fetched 2026-09-03 10:20 UTC. This page is also available as JSON at /api/data?ticker=LLY and is emitted with FAQPage structured data for machine reading.
For you
Charts, 10-year financials, peer comparison, screening and portfolio tracking for LLY and 5,000+ tickers.
